Background: Using data from the PACS 01 randomized trial, we evaluated the cost-effectiveness of anthracyclines plus docetaxel (Taxotere; FEC-D) versus anthracyclines alone (FEC100) in patients with node-positive breast cancer.
introduction
Breast cancer is the most common form of cancer and the second leading cause of cancer-related death among women [1] . Anthracyclines are known to be one of the most effective therapeutic agents for treating breast cancer, and the use of regimens such as 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) has become a standard of care in the adjuvant setting [2] . In the early 1990s, taxanes were introduced into clinical practice as a number of phase II studies indicated that this new agent might be particularly active in both first-and second-line metastatic breast cancer [3] [4] [5] . During the last few years, in view of the efficacy of both anthracyclines and taxanes when used as single agents for treating metastatic disease, various combinations of these two drugs have been tested in the adjuvant setting in order to maximize the efficacy of first-line treatment and improve the prognosis. Although some trials reported improvements in terms of disease-free survival (DFS) and overall survival (OS) in node-positive breast cancer patients after adding a taxane to the standard anthracycline-based regimen [6] [7] [8] , which led to this therapeutic strategy being widely used, the optimum strategy of taxane administration has not yet been established.
In oncology, the availability of promising but expensive treatments raises questions about the cost-effectiveness ratio in the context where experimental treatments often increase the cost of medical strategies without radically improving the outcome [9] . Cost-effectiveness considerations therefore play a growing role in decision making since it has become necessary to determine whether an innovative strategy is acceptable to society, with a cost-effectiveness ratio less than the per capita gross domestic product. The economic impact of alternative strategies is particularly important in the case of taxanes for breast cancer patients, where the benefits remain limited.
The aim of this study was therefore to assess the costeffectiveness of a six-cycle anthracycline-based chemotherapy (FEC100) versus a sequential regimen of three cycles of anthracyclines followed by three cycles of docetaxel (FEC-D) as adjuvant treatment of women with node-positive breast cancer.
This economic analysis was conducted alongside a phase III randomized trial (PACS 01), in which it was established that after 5 years of follow-up, the sequential use of docetaxel significantly improves DFS (78.3% versus 73.2%, P = 0.010) and OS (90.7% versus 86.7%, P = 0.017) in comparison with six cycles of FEC100 in node-positive breast cancer patients [10] .
patients and methods

the PACS 01 trial
The clinical effectiveness and medical resource utilization used in this costeffectiveness analysis were on the basis of data collected alongside the PACS 01 clinical trial. Patients included in this study were aged between 18 and 64, had histologically proven breast cancer with axillary lymph node involvement and no metastases. Patients randomly assigned to the FEC100 arm received six cycles of 5-fluorouracil 500 mg/m The patients gave their written informed consent before entry into the study and the protocol was approved by the ethical committee. The complete design and results of the PACS 01 study have been presented previously [10] .
cost-effectiveness analysis outcome. The primary end point of the PACS 01 study was 5-year DFS defined as the time from randomization until first relapse, contralateral breast cancer or death from any cause. Secondary end point was 5-year OS, defined as the time from randomization until death from any cause. The mean number of life-years and disease-free years was estimated in the two groups of patients as the area under the OS and DFS curves [11] .
In the perspective of an economic evaluation, the outcome of interest was mean survival, and effectiveness was measured in our cost-effectiveness analysis (CEA) in terms of mean quality-adjusted life years (QALYs). QALYs were estimated from OS and DFS by weighting each mean survival time by a utility value (ranging from 0 to 1) for the health states 'disease free', 'metastatic relapse' and 'locoregional relapse'. The utility values, which were 0.94, 0.5 and 0.74 for the three health states, respectively, were derived from the literature [12] . treatment costs. Economic evaluation was conducted from the French Hospital perspective and included only direct medical costs attributable to treatment. Direct nonmedical costs and indirect costs were not taken into consideration as we assumed that they were unlikely to differ between the two treatment strategies. The time horizon was that of the trial (5 years). Costs were calculated using the microcosting method, consisting in a measurement of resource utilization in physical quantities combined with a monetary valuation using unit cost data. Resource utilization included hospitalization stay, drugs (chemotherapy, antibiotics, growth factors and antiemetics), laboratory/imaging investigations and surgery act.
Monetary values attributed to the physical quantities consumed were obtained from several sources, which are specified below. The cost of hospitalization, which was calculated from a detailed observation of the annual expenditures of one hospital, included consumable supplies, cost of staff, food cost, depreciation of equipment (20% rate) and overheads. Drug prices were the purchase prices nationally negotiated by the Federation of French Cancer Hospitals. The costs of laboratory tests, diagnostic examinations and surgical interventions were determined using the French National Health Service's official tariffs. Unit price relates to the year 2006.
In order to take into account the differences in relapse rates between the two treatments compared, the cost of relapse was also introduced in the CEA, on the basis of a previous study [13] , in which the direct medical costs of relapse were assessed. We applied a recurrence cost to each of the patients who relapsed, depending on the type of relapse (metastatic or not). The cost of relapse was assumed to be the same regardless of the treatment arm. Cost of endocrine therapy was included in the 5-year cost.
incremental cost-effectiveness ratio. The incremental cost-effectiveness ratio (ICER) represents the additional cost required to reach an additional unit of effectiveness using the new treatment rather than the standard treatment. The ICER was calculated as the difference in mean costs (DC) divided by the difference in mean effect (DE). The ICER of using FEC-D versus FEC100 was calculated and expressed in terms of cost per QALY gained.
handling of uncertainty and sensitivity analysis
To account for the uncertainty due to sampling fluctuations, confidence regions around the ICER were calculated using the 'truncated Fieller's method' [14] , which can be used for decision making with satisfactory performances [15] .
Cost-effectiveness acceptability curves, which give an estimate of the probability that the strategy will be cost-effective given various values of society's willingness to pay, were also presented.
In addition, to deal with the uncertainty due to the various modeling hypotheses, several sensitivity analyses were carried out. First, since docetaxel is the major cost factor in the innovative strategy, we investigated whether a decrease in its unit cost would affect the results of the costeffectiveness analysis. This decrease was taken to range from 210% to 260%.
Secondly, as the relapse rate differed between arms, sensitivity analyses were conducted around some of the utility values used to weight survival to calculate QALYs. The utility value for the health state 'metastatic relapse' ranged from 0.3 to 0.7.
results
patients' characteristics
From June 1997 to March 2000, 1999 patients were included in the PACS 01 trial involving 85 centers in France and Belgium (996 in the FEC100 arm and 1003 in the FEC-D arm). Three patients did not receive the treatment and no economic data were available on these three patients; 1996 patients were therefore included in the cost-effectiveness analysis (995 in the FEC100 arm versus 1001 in the FEC-D arm). Patients' clinical characteristics are presented in Table 1 .
outcome Survival results of the PACS 01 trial in terms of OS and DFS are presented in Table 1 . Mean DFS was 68.1 months with strategy FEC100 versus 71.5 months with strategy FEC-D. Mean OS was 76.7 and 78.5 months with the two treatments, respectively. When utility adjustment was carried out, patients receiving FEC-D benefited from an additional 0.20 QALYs on average in comparison with those receiving FEC100 (5.9 versus 5.7, P = 0.0089).
cost results
The costs associated with both strategies and the proportion of the costs attributable to the various cost categories are summarized in Table 2 . The treatment cost with strategy FEC-D was significantly higher than that of the six-cycle course of anthracylines (P < 0.001). The mean total treatment cost of patients given FEC-D was €12 969 [95% confidence interval (CI) €12 780-€13 158] versus €9725 (95% CI €9609-€9843) in patients receiving FEC100, which amounts to an additional cost of 33.4%. As expected, the difference in total cost between treatments was due to the additional cost of taxanes: the cost of chemotherapy in the case of strategy FEC-D was nearly three times higher than that of strategy FEC100 (€5202 versus €1779, P < 0.001). There was no difference in the other costs between the two strategies (P >0.05 in all cases).
At a 5-year horizon (including the cost of relapse and followup), the difference in the mean costs between the two strategies was decreased, due to the reduced risk of recurrence in the FEC-D arm over a 5-year period (hazard ratio = 0.78; 95% CI 0.64-0.94, P = 0.01). Mean costs were €24 820 for FEC-D treatment versus €22 960 for FEC100 treatment, and the additional cost of FEC-D decreased to 18%.
incremental cost-effectiveness ratios. The results of the costeffectiveness analysis are presented in Table 3 . The confidence regions of the ICERs are shown graphically on the costeffectiveness plane in Figure 1 .
The incremental cost per QALY gained was estimated at €9665 and the upper limit of the CI was equal to €55 515, which is more than five times the point estimate. The costeffectiveness acceptability curve on the basis of 10000 replications of cost-effectiveness ratios is presented in Figure 2 . This figure shows the proportion of the estimated ICER replicates that fell below this critical threshold, as a function of various values of the society's willingness to pay for a QALY gained. The curve indicates that there is a 96.52% probability that the ICER will be <50 000€ per QALY, which is generally taken to be an acceptable threshold for health care interventions [16] [17] [18] .
sensitivity analysis. The sensitivity analysis shows that the ICER is sensitive to a decrease in the cost of docetaxel as it would reduce the up-front drug cost of strategy FEC-D and the costeffectiveness analysis would therefore become more favorable to this strategy. The various values of the cost per QALY gained and the associated CIs depending on the decrease in the cost of docetaxel are presented in Figure 3 , which shows that the cost per QALY gained decreased from €7497 to €23629 (situation of dominance) as the unit cost of docetaxel decreased from 10% to 60%. The upper bound of the ICER CI fell less than €50 000 per QALY gained (from €48 506 to €6390) as soon as the unit cost of docetaxel decreased from 8.3%.
Estimates of the cost per QALY gained were sensitive to the utility weight associated to the metastatic relapse health state ( Table 3 ). The ICERs ranged from €8610 to €11 170 per QALY gained when the utility value ranged from 0.3 to 0.7. When the utility value decreased, the cost-effectiveness of strategy FEC-D increased because the risk of recurrence was lower with this treatment. Conversely, when the utility value increased from 0.5 to 0.7, the ICER increased to €11 170, and the upper CI limit reached €95 680.
discussion
In this study, the cost-effectiveness of the FEC-D versus FEC100 strategy for treating node-positive breast cancer patients was investigated. The results showed that FEC-D treatment was associated with a higher level of resource use, due to the adjunction of taxanes, which increased the cost of chemotherapy. This extra cost was partly offset by the lower rate of recurrence observed among FEC-D patients, which decreased the cost differential during the 5-year follow-up period studied. The cost per relapse-free life-year gained was estimated at €11 258 (95% CI €6740-€33 209), which clearly argues in favor of strategy FEC-D. The cost per QALY gained ), using the log-rank test. original article Annals of Oncology was found to be €2372, with an upper CI limit equal to €55 515. An implicit threshold value that society is disposed to pay for health improvement commonly used in cost-effectiveness analyses is €50 000 per QALY gained [18, 19] . Interventions giving one additional QALY for less than €50 000 are generally taken to be cost-effective, those costing between €50 000 and €100 000 per QALY are of questionable cost-effectiveness and those costing more than €100 000 per QALY are not regarded as cost-effective, although these criteria are often challenged [20] [21] [22] . Considering that a value of €50 000 is an acceptable threshold, the probability of the FEC-D strategy being effective amounts to >96%.
The results of the sensitivity analysis exploring the impact of the unit price of docetaxel were in favor of the FEC-D strategy, with a decrease in the ICER point estimates as well as the upper CI limit. Decreasing the unit cost of docetaxel by 10% would bring the upper limit of the ICER CI below the acceptable threshold ratio of €50 000.
Few cost-effectiveness studies have been carried out so far to determine the economic benefits of administering docetaxel to node-positive (N+) patients. The present estimates are consistent with those presented in some recent studies on the cost-effectiveness of taxanes in the adjuvant setting [23] [24] [25] . Au et al. [23] have assessed the cost-effectiveness of adjuvant docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC), and the results argue in favor of the taxane-based regimen, which involved an incremental cost of Can $18 505 per QALY gained. In the study by Younis et al. [25] , where the clinical benefit used in the model was on the basis of the PACS 01 trial, the net incremental cost of FEC-D versus FEC100 was assessed at $3544 per patient during the treatment period and subsequently fell to $2280, taking the recurrences prevented into account. The incremental cost per QALY gained was $14 612, which is similar to our own estimates. The results of these two studies, along with the present findings, provide evidence that taxane-based chemotherapies such as FEC-D or TAC are cost-effective alternatives to therapeutic strategies based on anthracylines alone, such as FEC100, for nodepositive breast cancer patients. It is worth noting that our analysis involved a very large sample of patients (1996) on whom detailed information about the costs as well as the effectiveness of the treatments was available, which made our results highly consistent, although the presence of some bias obviously cannot be ruled out. This mean cost was calculated on the whole sample of patients, including those who did not receive tamoxifen. b The cost of local recurrence, metastatic recurrence and follow-up per patient were derived from the study by Cocquyt et al. [13] . ; SD, standard deviation; na, not applicable; G-CSF, granulocyte colony-stimulating factor; CI, confidence interval; NS, not significant. 
Annals of Oncology original article
One common weakness of quality-adjusted survival analyses is due to the valuation of health states in terms of utility. In this analysis, the utility of the survival time spent after the treatment was assumed to be <1 (0.94) as the patients were presumably not in perfect health, which corresponded to the value 1. The difficulty arising from the use of arbitrary utility values on the basis of the literature is that utilities differ considerably from one study to another [26] . These issues were addressed by carrying out sensitivity analyses on a range of utility values, which confirmed that although the ICER estimates differed, depending on the choice of utility values, the cost-effectiveness of the FEC-D strategy was not affected as our results were extremely robust. In addition, we decided not to weight the time spent receiving chemotherapy, although the utility associated with this period decreases due to the impact of adverse events on patients' quality of life (QOL). This decision was justified by the fact that both treatments included the same number of cycles and therefore duration of treatments was approximately similar. Assuming the same utility weight, the decrease in the QALY benefits would be identical in both arms, and this factor would therefore not affect the results of the analysis. Since each treatment is associated with its specific side-effects, patients may have been exposed to different toxic effects which impact their QOL; we might of course have adopted different utility values, depending on the treatment received. However, this potential impact is difficult to translate into utilities, and no chemotherapy regimen-specific utilities were available. original article
Annals of Oncology
In this study, the cost of relapse was derived from the literature, regardless of the treatment arm. The choice of chemotherapy regimen for treating relapses naturally depends strongly on the first-line chemotherapy administered, and the cost of recurrence can therefore vary between arms. In particular, patients to whom anthracylines alone were administered as first-line treatment are likely to be given taxanes if a recurrence occurs. This would lead to a higher cost of treating recurrence in these patients, which would balance the extra cost due to the use of taxanes in first-line chemotherapy. This might lead to some ICERs being even more favorable to strategy FEC-D. It should be noticed that the choice of endocrine therapy to treat relapse of hormonereceptor positive patients may represent a significant part of long-term costs, in particular with the use of aromatase inhibitors. This was not considered in this analysis.
Two other points certainly confirm that the use of taxanes for treating adjuvant breast cancer patients is cost-effective although it involves extra costs. First, Taxotere is currently covered by a patent, which will expire in 2010 in the United States and most European countries, and a generic version of this drug may become available soon. The price of drugs typically decreases by at least 30%-40% once the patent has expired, and the forthcoming drop in the price of docetaxel will predictably improve the cost-effectiveness of strategy FEC-D.
Secondly, recent developments of genomic test procedures to improve drug effectiveness by selecting patients who would experience the most benefit from a particular treatment [27] may lead to control chemotherapy cost escalation. In the case of taxane, better targeting the treatment to the patients who will benefit most may also increase the cost-effectiveness of this therapeutic strategy.
To conclude, assuming that the reduced rates of recurrence observed during the first 5 years in the FEC-D arm will translate into long-term OS benefits, this strategy can be considered a cost-effective alternative for treating N+ breast cancer patients despite the additional costs initially associated with this treatment, with ICERs below the acceptable threshold.
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